MedDeviceGuideMedDeviceGuide

Medical Device & IVD Blog

Quality Systems

ISO 13485 Audit Findings: Most Common Nonconformities by Clause and How to Prevent Them

The ISO 13485 clauses most cited in audit findings — root causes and corrective actions for document control, CAPA, design controls, suppliers, internal audits, and process validation.

Regulatory

FDA 510(k) Consultants: How to Choose, Vet, and Work with a Clearance Partner

How to select, evaluate, and engage an FDA 510(k) consultant — fees by device complexity, engagement models, red flags, due diligence checklist, and when hiring one makes financial sense.

Regulatory

FDA Adverse Event Monitoring System (AEMS): What Replaced MAUDE for Medical Devices

FDA replaces MAUDE with AEMS — unified adverse event dashboard, migration timeline, data limitations, and reporting changes for device manufacturers.

Quality Systems

Medical Device Software Verification vs Validation: FDA and IEC 62304 Requirements

Software verification vs validation for medical devices — FDA expectations, IEC 62304 activities, documentation, traceability, and the design control process.

Regulatory

FDA 510(k) Clearances: Tracking, Timelines, and Decision Data

Track FDA 510(k) clearances, understand review timelines, interpret SE/NSE decisions, use the 510(k) database, and apply clearance statistics to your 2026 regulatory strategy.

Regulatory

FDA 510(k) Guidance Documents: Device-Specific Requirements and Special Controls

How to find and use FDA 510(k) guidance documents, Class II special controls, device-specific submission requirements, and the CDRH FY 2026 guidance agenda to prepare stronger premarket submissions.

Regulatory

FDA Medical Device Registration: Step-by-Step Process from Classification to Market

Step-by-step FDA medical device registration — classification, 510(k)/De Novo/PMA pathways, establishment registration, device listing, FY 2026 fees, and post-market obligations.

Regulatory

Dermal Fillers vs Cosmetics vs Medicines: Hong Kong Borderline Classification After GN-00

How Hong Kong classifies injectable dermal fillers at the borderline between medical devices, cosmetics, and medicines — and why the May 2026 GN-00 update matters for your product.

Quality Systems

eDHR for Medical Devices: QMSR, Part 11 & Digital Manufacturing (2026)

eDHR implementation guide for medical device manufacturers: QMSR requirements, 21 CFR Part 11, MES integration, ISO 13485, paper-to-digital migration, and inspection readiness.

Biocompatibility

NAMs for Medical Device Biocompatibility: FDA, EU & ISO 10993 Guide (2026)

NAMs for medical device biocompatibility: FDA roadmap, EU phase-out plan, ISO 10993-5/-10/-23 in vitro alternatives, chemical characterization, and regulatory strategy.

Regulatory

Hong Kong Dermal Filler MDACS Listing Strategy: LRP, Docs, Importers, Procurement

Guide to listing injectable dermal fillers under Hong Kong MDACS after the May 2026 GN-00 update: LRP, technical dossier, importer controls, adverse event reporting, and procurement.

Regulatory

Hong Kong MDACS GN-00 Update: Why Injectable Dermal Fillers Are Now Medical Devices

On 13 May 2026, Hong Kong MDD updated GN-00 to classify injectable dermal fillers as medical devices under MDACS. What changed, why it matters, and what manufacturers must do.

Digital Health & AI

RPM Device Regulatory Pathway: FDA, CMS Reimbursement & EU MDR (2026)

RPM device regulation: FDA classification, CMS 2026 CPT codes (99445, 99470), reimbursement rates, SaMD, EU MDR pathway, and commercialization strategy for connected monitoring devices.

Industry News

Abbott Libre Duo CE Mark: Dual Glucose-Ketone CGM Strategy (2026)

Abbott Libre Duo CE mark analysis covering the first continuous glucose-ketone sensor, dual-analyte regulatory strategy, CGM competition, FDA pathway, and wearable convergence.

Regulatory

EU Digital Product Passport for Medical Devices: ESPR, Batteries, and UDI

Guide to EU Digital Product Passport requirements for medical devices, including ESPR scope, battery passports, UDI/EUDAMED links, standards, and timelines.

IVD & Diagnostics

Liquid Biopsy and Multi-Cancer Early Detection (MCED) Tests: FDA, IVDR Regulatory Pathway

Regulatory guide to liquid biopsy and MCED tests, including FDA pathways, Breakthrough designation, companion diagnostics, EU IVDR classification, clinical evidence, and key market players.

M&A & Funding

Quantum Surgical Acquires NeuWave Medical: Precision IO and Robotic Ablation

Quantum Surgical's 2026 NeuWave acquisition pairs Epione robotic ablation with microwave ablation technology under Precision IO Group for interventional oncology.

Post-Market Surveillance

Swissmedic 2026 PMS Focus Campaign: What Class IIa/IIb/III Manufacturers Must Prepare Now

Swissmedic 2026 PMS focus campaign guide for Class IIa, IIb, and III devices, covering PMS plans, PSURs, PMCF data, complaints, trend analysis, and preparation.

M&A & Funding

Thermo Fisher Microbiology Divestiture to Astorg: $1.1B Deal Analysis

Analysis of Thermo Fisher's $1.1B microbiology divestiture to Astorg, including deal terms, Oxoid and Remel assets, $645M revenue, and diagnostics strategy.

Regulatory

EUDAMED Mandatory Registration: May 28, 2026 Deadlines and UDI Steps

Guide to mandatory EUDAMED registration from May 28, 2026, including actor registration, UDI/device data, certificate linkage, legacy device deadlines, and action steps.